LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living ...

Alcon to Acquire LumiThera and its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD) ...

Sean Clark, the VP and general manager of Alcon’s Global Surgical Franchise, added: “Dry AMD is an area of significant unmet ...

HOUSTON, TX / ACCESS Newswire / July 9, 2025 / Mann Eye Institute, a leader in innovative eye care since the 1970s, is proud ...

Alcon has inked a deal to acquire LumiThera and its light-based therapy for dry age-related macular degeneration, which obtained a groundbreaking FDA clearance late last year. | LumiThera's approach ...

LumiThera, Inc. is a medical device company focused on diagnosing, treating, and monitoring ocular disease and damage including dry age-related macular degeneration (AMD), a leading cause of ...

Medical device startup LumiThera raised $1.15 million as part of a new fundraising round, according to a new SEC filing. The Poulsbo, Wash.-based company ...

LumiThera wants patients to have access to non-invasive Valeda treatments to improve vision and address the disease earlier in the process,” stated Clark Tedford, Ph.D., LumiThera President and CEO.

LumiThera’s Valeda became the first non-invasive approach for treating dry AMD following its authorisation by the US Food and Drug Administration (FDA) in November 2024.

LumiThera said March 3 that Diopsys is now a wholly-owned subsidiary. The acquisition is expected to create a complementary diagnosis and monitoring platform to LumiThera’s Valeda treatment platform.

This is a developing news story. Please check back soon for updates. Alcon will acquire LumiThera, including its ...

Monday announced its intention to acquire LumiThera and its PBM device for the treatment of early and intermediate dry AMD.